At present, there are no oral factor B inhibitors approved in the United States that are known for introducing groundbreaking products that have set new industry standards. The development landscape for this class of drugs is still emerging [1].
What are Factor B inhibitors and why are they important?
Factor B is a protein that plays a key role in the complement system, a part of the immune system. Inhibiting Factor B is a strategy being explored for treating various inflammatory and autoimmune diseases by dampening excessive complement activation, which can damage tissues [1].
What is the current status of oral Factor B inhibitor development?
Research and clinical trials are ongoing for oral Factor B inhibitors. These drugs are being investigated for conditions such as atypical hemolytic uremic syndrome (aHUS), geographic atrophy (GA) secondary to age-related macular degeneration (AMD), and lupus nephritis [1][2]. However, as of now, no specific oral Factor B inhibitor has reached the market and established new industry standards.
Which companies are developing oral Factor B inhibitors?
Several companies are actively involved in the research and development of oral Factor B inhibitors. These include Apellis Pharmaceuticals, which has an investigational drug for GA, and companies like ChemoCentryx (now part of Amgen) and Akari Therapeutics, which have explored Factor B inhibitors for different indications [1][3]. The exact timelines for potential market entry and the impact of these future products remain to be seen.
How do oral Factor B inhibitors differ from other complement inhibitors?
Oral Factor B inhibitors represent an advancement in complement inhibition because they offer the potential for oral administration, which is generally more convenient for patients than injectable therapies. Other complement inhibitors in development or on the market target different components of the complement cascade, such as C5, or are administered via injection [1]. The oral route of administration for Factor B inhibitors, if successful, could significantly change treatment paradigms for complement-mediated diseases.